1700008A04Rik Inhibitors
Chemical inhibitors of 1700008A04Rik can interfere with the protein's function through various molecular interactions and signaling pathway disruptions. Wortmannin and LY294002, for instance, target phosphoinositide 3-kinases (PI3K), pivotal in the activation of downstream signaling pathways. By inhibiting PI3K, these chemicals can prevent the transmission of signals essential for the activities of 1700008A04Rik, leading to its functional inhibition. Rapamycin, on the other hand, acts upon the mammalian target of rapamycin (mTOR), a kinase integral to cell growth and survival pathways. By inhibiting mTOR, Rapamycin can suppress the pathways that are essential for the functionality of 1700008A04Rik.
In a similar vein, Alsterpaullone targets cyclin-dependent kinases (CDKs), which are essential for cell cycle progression. Inhibition of these kinases can halt cell cycle-related processes that 1700008A04Rik may regulate. PD98059 and U0126 both selectively inhibit MEK in the MAPK/ERK pathway; by blocking this route, they can prevent 1700008A04Rik from participating in essential signaling processes. SB203580 and SP600125 inhibit p38 MAP kinase and JNK, respectively, impeding stress response signaling pathways that 1700008A04Rik may be involved in. Erlotinib and Gefitinib obstruct the epidermal growth factor receptor (EGFR) tyrosine kinase, and by doing so, they can inhibit signaling pathways that 1700008A04Rik may rely upon. Lastly, Sorafenib targets multiple kinases, including RAF in the RAF/MEK/ERK pathway, while Triciribine inhibits AKT phosphorylation, crucial for cell survival and metabolism signaling pathways, leading to the functional inhibition of 1700008A04Rik by blocking the signals it requires for activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways. Inhibition of PI3K by Wortmannin would lead to functional inhibition of 1700008A04Rik by preventing activation of downstream signals that rely on PI3K. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that regulates cell growth and survival. By inhibiting mTOR, Rapamycin would suppress the pathways that are essential for the activity of 1700008A04Rik, leading to its functional inhibition. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs), which are critical for cell cycle progression. Inhibition of CDKs can lead to functional inhibition of 1700008A04Rik by preventing cell cycle-related processes that 1700008A04Rik may regulate. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of MEK leads to the blockade of the MAPK/ERK signaling route, resulting in the functional inhibition of 1700008A04Rik if it relies on this pathway for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in stress response and cytokine production. The inhibition of p38 MAPK can cause functional inhibition of 1700008A04Rik by blocking the signaling processes it participates in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor like Wortmannin. It prevents PI3K from activating downstream pathways, which would inhibit the function of 1700008A04Rik by blocking essential signals for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the stress-activated protein kinase pathway. By inhibiting JNK, SP600125 could functionally inhibit 1700008A04Rik by impeding the signaling cascade that it may operate within. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. By blocking EGFR signaling, Erlotinib would functionally inhibit 1700008A04Rik if it is involved in EGFR-mediated signal transduction. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases, including RAF, which is part of the RAF/MEK/ERK pathway. By inhibiting RAF kinases, Sorafenib would lead to functional inhibition of 1700008A04Rik by disrupting signaling that relies on this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, like PD98059, is a selective inhibitor of MEK. The inhibition of MEK would prevent the activation of the MAPK/ERK pathway, thereby functionally inhibiting 1700008A04Rik by blocking essential signals for its activity. | ||||||